In jurisdictions as large and diverse as California, the understanding of health equity and how to apply best practices could not be more pressing. Improving and assuring racial equity above racial equality has been shown to reduce inequity in healthcare outcomes through community-level investment, equitable leadership development, and most importantly increased access to timely and..
By BioMarin Pharmaceutical Inc. VOXZOGO is a recombinant C-type natriuretic peptide (CNP) analog that has been modified to resist neutral endopeptidase degradation and enhance half-life. In 2021, VOXZOGO was approved for treatment of patients 2 years of age and older with Achondroplasia and open growth plates in the EU and under accelerated approval by US..
Location: Live / Online 8 AM PST / 11:00 AM EDT (North America) Innovative new treatments with the potential to improve patients’ lives face unprecedented obstacles, including greater complexity and cost, more stringent evidence requirements to secure patient access beyond regulatory approval, a greater diversity of stakeholders and decision-makers, and competition for share of voice...
Location: Live / Online 8am PST (N. America) / 11am EDT (N. America) / 4pm BST (UK) / 5pm CEST (EU-Central) Shifting expectations in the healthcare industry have put a considerable focus on scientific innovations driven by the end user. This new structure, combined with ongoing commitments to maintain scientific integrity, has created a new..
The number of biopharma and biotech companies developing and launching new therapies is continuing to rise with emerging biopharma remaining a strong source of innovation. At the same time, more barriers to success are emerging with requirements for increasingly complex clinical trials, continuous regulatory changes, evolving payer conditions, and more restrictive access to HCPs. It’s..
The number of biopharma and biotech companies developing and launching new therapies is continuing to rise with emerging biopharma remaining a strong source of innovation. At the same time, more barriers to success are emerging with requirements for increasingly complex clinical trials, continuous regulatory changes, evolving payer conditions, and more restrictive access to HCPs. It’s..
The number of biopharma and biotech companies developing and launching new therapies is continuing to rise with emerging biopharma remaining a strong source of innovation. At the same time, more barriers to success are emerging with requirements for increasingly complex clinical trials, continuous regulatory changes, evolving payer conditions, and more restrictive access to HCPs. It’s..
The number of biopharma and biotech companies developing and launching new therapies is continuing to rise with emerging biopharma remaining a strong source of innovation. At the same time, more barriers to success are emerging with requirements for increasingly complex clinical trials, continuous regulatory changes, evolving payer conditions, and more restrictive access to HCPs. It’s..
Kwame Ulmer is a 12 year veteran of the FDA and currently works as a regulatory strategist and investor. You will learn how to develop a regulatory strategy, maximize your..